Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for gastrointestinal and rare diseases, with a focus on addressing significant unmet medical needs. The company's primary revenue driver is LINZESS (linaclotide), an FDA-approved treatment for irritable bowel syndrome with constipation, chronic idiopathic constipation, and functional constipation, which is marketed internationally through partnerships with AbbVie, Astellas Pharma, and AstraZeneca in various territories. Ironwood generates revenue primarily through collaborative arrangements and royalties from pharmaceutical partners rather than direct sales, while advancing its pipeline with apraglutide, a next-generation therapy for short bowel syndrome, and maintaining a strategy focused on maximizing its existing commercialized products while ensuring sustained profitability and cash flow generation.